

ForPatients

by Roche

Diffuse Large B-Cell Lymphoma (DLBCL) Chronic Lymphocytic Leukemia

A study to look at how safe was it to give people with blood cancer (non-Hodgkin's lymphoma and chronic lymphocytic leukemia) – different doses of a study medicine (fenebrutinib)

Trial Status
Completed

Trial Runs In
2 Countries

Trial Identifier
NCT01991184 GO29089

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This clinical trial was done to study a new medicine (fenebrutinib) for the treatment of patients with blood cancer. This was a phase 1, dose-escalation study to find out which dose of fenebrutinib was safe and tolerable for people with B-cell non-Hodgkin's lymphoma (B-NHL) and chronic lymphocytic leukemia (B-CLL). Twenty-four people with B-NHL or B-CLL – that had come back (relapsed) or did not respond to medicine (refractory) – where the disease had gotten worse (progressed) even after getting available medicines – and for which no other effective medicine was available – took part in this study. The study took place at nine study centers in two countries – USA and Australia.

Genentech, Inc. (Part of F. Hoffmann-La Roche Ltd., Switzerland)
Sponsor

Phase 1
Phase

NCT01991184 GO29089
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=18 Years

Healthy Volunteers
No
